Andrew Sloan, MD
- Medical Director, Neuro-Oncology
- Director, Brain Tumor and Neuro-Oncology Center
- Vice Chairman, Department of Neurological Surgery
Andrew E. Sloan, MD, FAANS, FACS, is a board certified neurosurgeon, physician-scientist, and educator at University Hospitals Cleveland Medical Center and UH Seidman Cancer Center. He is Director of the Brain Tumor and Neuro-Oncology Center at UH Seidman Cancer Center and the Neurological Institute. He serves as Professor and Vice-Chair of Neurosurgery at Case Western Reserve University School of Medicine, with joint appointments in Pathology and the Center for Translational Neuroscience. He holds the Peter D. Cristal Endowed Chair in Neurosurgery at UH.
Dr. Sloan joined UH, Case Western Reserve, and the Case Comprehensive Cancer Center in 2007. Prior to coming to Cleveland, he was on faculty at the University of South Florida H. Lee Moffitt Cancer Center and Research Institute in Tampa, Fla., as well as Wayne State University and the Karmanos Cancer Institute in Detroit, Mich.
After graduating Yale University with a degree in biology (magna cum laude) and receiving his MD from Harvard Medical School, Dr. Sloan served his internship in general surgery and neurosurgical residency at UCLA followed by a fellowship in neurosurgical oncology at the M.D. Anderson Cancer Center in Houston.
His clinical and research interest focus on the biology and treatment of tumors of the brain and spine.
He has been recognized by his peers as one of the “Best Doctors in America” since 2003, and as one of the “Top Surgeons in America” since 2007. In 2014, he was elected President of the Ohio State Neurosurgical Society (OSNS).
His research on glioma vaccines and glioma stem cells has been funded by the National Institutes of Health (NIH), National Cancer Institute (NCI), the Ohio Third Frontier organization, American Society of Clinical Oncology (ASCO), American Brain Tumor Association (ABTA), Adult Brain Tumor Consortium (ABTC), Howard Hughes Medical Institute (HHMI) and other national organizations, and he is currently helping to develop a new generation of neurosurgical simulators.
He has authored more than 135 publications in peer-reviewed journals, as well as numerous editorials, reviews and book chapters, made more than 525 invited presentations, and holds four patents and investigational new drug (IND) applications.
He serves on the editorial board of several neurosurgical and scientific journals and is active in national surgical organizations, including the American Association of Neurological Surgery (AANS) and American College of Surgeons Oncology Group (ACOSOG). He appears regularly on national news broadcasts as a brain cancer expert.
- Benign Brain Tumors
- Laser Interstitial Thermotherapy
- Malignant Brain Tumors
- Minimally Invasive Brain Surgery
- Spinal Oncology
- Tumor Vaccines (Immunotherapy)
Patient Satisfaction Reviews
4.2 out of 5
- Neurological Surgery - American Board of Neurological Surgery
Fellowship | Neurosurgical Oncology
Neurosurgical Oncology - University Of Texas Md Anderson Cancer Center (1997 - 1998)
Residency | Neurological Surgery
Neurological Surgery - Ucla David Geffen School Of Medicine/Ucla Medical Center (1991 - 1997)
Internship | General Surgery
General Surgery - Ucla David Geffen School Of Medicine/Ucla Medical Center (1990 - 1991)
Harvard Medical School (1990)
Yale University (1985)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Andrew Sloan disclosed the following Outside Relationships with Industry:
- - Surgical Theater - Ownership